Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 15/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.64 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8083646 | 0.94 | VDR (0.69) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL8095556 | 0.85 | VDR (0.62) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL8095559 | 0.85 | VDR (0.62) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL8090194 | 0.85 | VDR (0.62) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL8098186 | 0.85 | VDR (0.62) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL8090365 | 0.85 | VDR (0.62) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL8090209 | 0.85 | VDR (0.62) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL8090198 | 0.85 | VDR (0.62) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL8090213 | 0.85 | VDR (0.62) | VDRHDAC6HDAC3HDAC2CYP24A1 | |
| SCHEMBL8090369 | 0.85 | VDR (0.62) | VDRHDAC6HDAC3HDAC2CYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6043385-A | TREATMENT OF PSORIASIS, BASAL CELL CARCINOMAS, DISORDERS OF KERATINIZATION AND KERATOSIS, NEOPLASTIC DISEASES SUCH AS LEUKEMIA, DISORDERS OF THE SEBACEOUS GLANDS SUCH AS ACNE AND SEBORRHOIC DERMATITIS, OSTEOPOROSIS, HYPERPARATHYROIDISM | HOFFMAN-LA ROCHE INC. (US) | 2000-03-28 | — | — | US | claimed |
| US-6043385-A | TREATMENT OF PSORIASIS, BASAL CELL CARCINOMAS, DISORDERS OF KERATINIZATION AND KERATOSIS, NEOPLASTIC DISEASES SUCH AS LEUKEMIA, DISORDERS OF THE SEBACEOUS GLANDS SUCH AS ACNE AND SEBORRHOIC DERMATITIS, OSTEOPOROSIS, HYPERPARATHYROIDISM | HOFFMAN-LA ROCHE INC. (US) | 2000-03-28 | — | — | US | disclosed |